Join        Login             Stock Quote

Amgen (AMGN) Gains After Better-Than-Expected Q1

 April 24, 2012 05:14 PM

Amgen Inc. (NASDAQ:AMGN), a biotechnology medicines company, reported a 5% increase in first quarter earnings, reflecting broad strength across the portfolio and a 8% growth in product sales. Adjusted earnings and revenue exceeded Street's expectations, sending its shares up 0.42% in aftermarket.

Earnings for the first quarter were $1.18 billion or $1.48 per share, up from $1.13 billion or $1.25 per share last year. Adjusted earnings rose to $1.29 billion or $1.61 per share from $1.26 billion or $1.34 per share.

Revenue increased 9% to $4.048 billion. Analysts had expected a profit of $1.45 per share on revenue of $3.93 billion.

[Related -Amgen, Inc. (NASDAQ:AMGN): What Will Drive Amgen This Year?]

U.S. product sales increased 8% to $3.0 billion, while International product sales rose 8% to $904 million. The impact of foreign exchange on international product sales for the first quarter of 2012 was not material.

Research & Development (R&D) expenses increased 3% to $723 million, due to higher costs associated with supporting later-stage clinical programs including AMG 145, AMG 785 and talimogene laherparepvec. This increase was offset partially by reduced expenses in Discovery Research and Translational Sciences.

Capital expenditures for the first quarter were $129 million, up from $100 million last year.

AMG 145 is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove LDL-C from the blood causing bad cholesterol to increase. AMG 785 is being developed to treat postmenopausal osteoporosis.

[Related -Amgen, Inc. (AMGN) Q3 Earnings Preview: Pipeline In Focus]

Looking ahead into the fiscal 2012, the company continues to anticipate revenue of $16.1 billion to $16.5 billion, and adjusted earnings of $5.90 to $6.15 per share, while Street predicts profit of $6.05 per share on revenue of $16.23 billion. The adjusted earnings excludes certain expenses related to acquisitions and cost-savings initiatives, non-cash interest expense associated with convertible notes and certain other items.

With respect to other guidance, Amgen still expects adjusted tax rate for 2012 to be in the range of 14% to 15%. Excluding the Puerto Rico excise tax, Amgen still projects adjusted tax rate for 2012 of 19% to 20%. The company still expects 2012 capital expenditures to be about $700 million.

AMGN closed Tuesday's regular trading up 0.50% at $68.63. The stock has been trading between $47.66 and $70.00 for the past 52 weeks.



Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageAutomating Ourselves To Unemployment

In this current era of central planning, malincentives abound. We raced to frack as fast we could for the read on...

article imageFed: Waiting For June… Or Godot?

The Federal Reserve left interest rates unchanged yesterday, as widely expected. But the possibility of a read on...

article imageThe Single Best Place To Invest Your Money For Retirement

It was never supposed to be this daunting. At least that's what we were read on...

article imageNegative Blowback From Negative Interest Rates

The Federal Reserve is widely expected to leave interest rates unchanged today. But perhaps standing pat read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.